Nearly 90,000 bottles of children’s ibuprofen voluntarily recalled
Bottles of children’s ibuprofen, made for Taro Pharmaceuticals U.S.A., Inc., are being recalled due to the potential presence of a foreign substance. (NIH)
(NEW YORK) — Nearly 90,000 bottles of children’s ibuprofen are being voluntarily recalled due to the potential presence of a foreign substance.
According to a notice from the Food and Drug Administration, Taro Pharmaceuticals U.S.A., Inc. received complaints from customers who reported “a gel-like mass and black particles” in the drug products.
Four-ounce (120 ml) bottles of Children’s Ibuprofen Oral Suspension are impacted by the recall. The FDA said the children’s medications, intended for pain relief from the common cold, flu, sore throat, headache and toothache and a fever reducer, were manufactured in India for Taro Pharmaceuticals U.S.A., Inc.
Recalled children’s ibuprofen products have lot codes of: 7261973A and 7261974A and bear an expiration date of 01/31/2027, according to the federal agency.
The FDA is classifying the recall as a Class II, which the agency defines as anything where the “use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.”
ABC News has reached out to Taro Pharmaceuticals and its parent company Sun Pharma for comment.
Stock photo of people commuting on e-bikes and scooters. (Maskot/STOCK PHOTO/Getty Images)
(NEW YORK) — E-bikes and e-scooters led to a growing number of trauma injuries at one New York City hospital, according to a new study published Wednesday.
About 7% of all trauma visits between 2018 and 2023 at Bellevue Hospital Center were due to micromobility injuries. Micromobility is the use of small, lightweight and low-speed modes of transportation such as bicycles, e-bikes and e-scooters.
The study showed a growing share of patients who sustained these injuries had accidents linked to e-bikes or e-scooters.
Hospital data showed that, by 2023, over half of all trauma cases related to bikes or scooters involved an e-bike or e-scooter, an increase from just 8% in 2018, according to the study, published in the journal Neurosurgery.
The most common type of mechanism involved a collision with a motor vehicle followed by falls from the bike or scooter.
Bellevue is a Level 1 Trauma center in a large metropolitan city, designed to treat the worst kinds of injuries. Over the study period, about 30% of patients suffered a traumatic brain injury, 26% had injury to the skull or face and 50% required surgery.
“Our study shows that micromobility injuries are producing serious brain and spinal trauma that demands neurosurgical care at a scale we haven’t seen before,” corresponding study author Dr. Hannah Weiss, a resident in the Department of Neurosurgery at NYU Grossman School of Medicine, said in a press release. “In a busy urban setting, we are seeing more and more of these injuries firsthand.”
Most patients seen for these injuries, nearly 69%, needed to be admitted to the hospital and nearly a third needed intensive care.
The majority of patients stayed at least three days in the hospital. Pedestrians who were struck had higher rates of traumatic brain injuries and were more likely to be admitted for intensive care.
“The data point to actionable solutions — helmet use, safer bike lane design and enforcement — that could prevent many of these injuries and better protect both riders and pedestrians, who in our study often sustained even more severe brain injuries than the riders themselves,” Weiss said.
About 20% of patients were intoxicated with alcohol, only 31% were using a helmet and injuries were more likely to occur in the evening hours, according to the study.
“Our findings make clear that urban infrastructure must continue to improve to keep pace with the rapid rise of electric bikes and scooters,” Dr. Paul P. Huang, an associate professor in the department of neurosurgery at NYU Grossman School of Medicine and chief of neurosurgery at NYC Health + Hospitals/Bellevue, said in a press release.
“Future studies should track these injuries across multiple cities and measure whether protected bike lanes, helmet programs, and speed enforcement actually reduce the number of brain and spine surgeries we perform,” Huang added,
Jade A. Cobern, MD, MPH, is a practicing physician, board-certified in pediatrics and general preventive medicine, and is a fellow of the ABC News Medical Unit.
Signs point the way to measles testing in the parking lot of the Seminole Hospital District across from Wigwam Stadium on February 27, 2025 in Seminole, Texas. Jan Sonnenmair/Getty Images
(NEW YORK) — There have been at least 733 confirmed measles cases reported across the nation, the latest data from the Centers for Disease Control and Prevention showed Friday.
In just a few weeks, the United States reported four times as many cases than typically seen throughout an entire calendar year.
Before last year, which had a record breaking 2,276 cases, the U.S. averaged 180 cases annually since measles was declared eliminated in 2000.
The record numbers come as South Carolina is dealing with the largest outbreak recorded in recent memory.
Other states that have reported cases and are dealing with ongoing outbreaks include Arizona, California, Florida, Georgia, Idaho, Kentucky, Minnesota, Nebraska, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, South Dakota, Utah, Virginia, Washington, and Wisconsin.
Most of the outbreaks occurring across the country are in pockets of under-vaccinated or unvaccinated communities.
The rate of kindergartners vaccinated with the measles, mumps, and rubella (MMR) vaccine has fallen from 95% in 2019 to below 93% in 2025, CDC data shows. Herd immunity, a threshold for vaccination rates that slow a virus’ ability to spread, is typically achieved at 95% vaccination rates, public health experts say.
Declining vaccination rates have left approximately 300,000 kindergarteners unprotected from measles infection.
The MMR vaccine is given in two doses, the initial shot given after the first year of life and the second shot given after the fourth year of life.
This is a developing story. Check back for updates.
(WASHINGTON) — Dr. Jay Bhattacharya, director of the National Institutes of Health (NIH), will take over as acting director of the Centers for Disease Control and Prevention, a White House official and sources familiar with the matter told ABC News.
Bhattacharya will continue in his current duties as NIH director until a permanent CDC director is nominated and confirmed, according to the White House official.
He replaces Jim O’Neill, who served as acting director of the CDC from late August 2025 until he stepped down last week.
O’Neill will be nominated as the next head of the National Science Foundation, according to the White House official.
